These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20444257)

  • 21. Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.
    Pezzolo A; Rossi E; Gimelli S; Parodi F; Negri F; Conte M; Pistorio A; Sementa A; Pistoia V; Zuffardi O; Gambini C
    Neuro Oncol; 2009 Apr; 11(2):192-200. PubMed ID: 18923191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma.
    Yu M; Ohira M; Li Y; Niizuma H; Oo ML; Zhu Y; Ozaki T; Isogai E; Nakamura Y; Koda T; Oba S; Yu B; Nakagawara A
    Int J Oncol; 2009 Apr; 34(4):931-8. PubMed ID: 19287950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPM1D is a potential target for 17q gain in neuroblastoma.
    Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
    Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
    Van Roy N; Van Limbergen H; Vandesompele J; Van Gele M; Poppe B; Salwen H; Laureys G; Manoel N; De Paepe A; Speleman F
    Genes Chromosomes Cancer; 2001 Oct; 32(2):126-35. PubMed ID: 11550280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
    Mosse YP; Greshock J; Margolin A; Naylor T; Cole K; Khazi D; Hii G; Winter C; Shahzad S; Asziz MU; Biegel JA; Weber BL; Maris JM
    Genes Chromosomes Cancer; 2005 Aug; 43(4):390-403. PubMed ID: 15892104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
    Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
    Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.
    Suo C; Deng W; Vu TN; Li M; Shi L; Pawitan Y
    Biol Direct; 2018 Jul; 13(1):14. PubMed ID: 30012197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.
    Ruano Y; Mollejo M; Ribalta T; Fiaño C; Camacho FI; Gómez E; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
    Mol Cancer; 2006 Sep; 5():39. PubMed ID: 17002787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
    Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
    Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
    Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays.
    Squire JA; Pei J; Marrano P; Beheshti B; Bayani J; Lim G; Moldovan L; Zielenska M
    Genes Chromosomes Cancer; 2003 Nov; 38(3):215-25. PubMed ID: 14506695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment.
    Hirai M; Yoshida S; Kashiwagi H; Kawamura T; Ishikawa T; Kaneko M; Ohkawa H; Nakagawara A; Miwa M; Uchida K
    Genes Chromosomes Cancer; 1999 Jul; 25(3):261-9. PubMed ID: 10379872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.